

Form 51-102F3

MATERIAL CHANGE REPORT

**Section 7.1 of National Instrument 51-102
Continuous Disclosure Obligations**

ITEM 1: NAME AND ADDRESS OF REPORTING ISSUER

Trimel Pharmaceuticals Corporation (the "**Corporation**")
2488 Dunwin Drive
Mississauga, Ontario
L5L 1J9

ITEM 2: DATE OF MATERIAL CHANGE

August 8, 2011.

ITEM 3: NEWS RELEASE

A press release was issued by the Corporation on August 3, 2011. A copy of the press release is attached hereto as Schedule A.

ITEM 4: SUMMARY OF MATERIAL CHANGE

Effective August 8, 2011, the Corporation appointed Tom Rossi to the newly created position of President.

ITEM 5: FULL DESCRIPTION OF MATERIAL CHANGE

Effective August 8, 2011, the Corporation appointed Tom Rossi to the newly created position of President.

Mr. Rossi is 47 years old, a native of Montreal, Canada where he graduated from McGill University having majored in Microbiology and Immunology. Mr. Rossi later obtained his MBA from Concordia University in Montreal.

Mr. Rossi has over 23 years experience in the pharmaceutical industry in Canada and abroad. In his career, he has worked for companies such as Johnson & Johnson, Boehringer Mannheim, Merck & Co. and most recently Novartis. Mr. Rossi's career has been marked by successful performance and a continued expansion of his responsibilities. At Novartis, he held the positions of Senior Vice President and Chief Operating Officer for their Canadian operations followed by Country President and CEO for Novartis Pharmaceuticals in Belgium. Then, as CEO for Novartis Pharmaceuticals Canada Inc., Mr. Rossi led Canada's fourth largest pharmaceutical company with annual sales in excess of \$800 million and over 700 employees while delivering significant levels of profitability to the corporation.

ITEM 6: RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102

Not applicable.

ITEM 7: OMITTED INFORMATION

Not applicable.

ITEM 8: EXECUTIVE OFFICER

The following executive officer of the Company is knowledgeable about the material change and this report:

Kenneth G. Howling
Chief Financial Officer
(416) 679-0536

ITEM 9: DATE OF REPORT

August 9, 2011

SCHEDULE A

(See attached.)



Contact: Kenneth G. Howling
Chief Financial Officer
416 679 0771

FOR IMMEDIATE RELEASE

TRIMEL PHARMACEUTICALS CORPORATION APPOINTS TOM ROSSI AS PRESIDENT

Toronto, Canada, August 3, 2011 – Trimel Pharmaceuticals Corporation today announced that Mr. Tom Rossi has joined the Company effective August 8, 2011 in the newly created position of President. Mr. Rossi is 47 years old, a native of Montreal, Canada where he graduated from McGill University having majored in Microbiology and Immunology. Mr. Rossi later obtained his MBA from Concordia University in Montreal.

Mr. Rossi has over 23 years experience in the pharmaceutical industry in Canada and abroad. In his career, he has worked for companies such as Johnson & Johnson, Boehringer Mannheim, Merck & Co. and most recently Novartis. Mr. Rossi's career has been marked by successful performance and a continued expansion of his responsibilities. At Novartis, he held the positions of Senior Vice President and Chief Operating Officer for their Canadian operations followed by Country President and CEO for Novartis Pharmaceuticals in Belgium. Then, as CEO for Novartis Pharmaceuticals Canada Inc., Mr. Rossi led Canada's fourth largest pharmaceutical company with annual sales in excess of \$800 million and over 700 employees while delivering significant levels of profitability to the corporation.

Chairman of the Board and Chief Executive Officer Bruce Brydon commented, "In Tom, the Company has found that special executive who brings the experience of the large corporate environment, yet has maintained the spirit of the entrepreneur along with the capacity to make a difference, create value and help grow our Company. He also brings significant industry skills, knowledge and added international contacts to Trimel. We look forward to benefitting from Tom's commitment and contribution across all aspects of our business."

About Trimel

Trimel Pharmaceuticals Corporation (TSX: TRL) is a leader in developing quality of life pharmaceuticals, targeting conditions related to Aging, Well Being and Female Sexual Health. Trimel is developing multiple product opportunities, including Compleo TRT, an intranasal bio-adhesive Testosterone gel for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.